A Randomized Controlled Trial of Effects of DAIry PROtein Products on Liver Disease Severity and Metabolism in Patients With Non-Alcoholic Fatty Liver Disease.

Metabolic Syndrome Clinical Trial

— DAIPRO-NAFLD  

Official title:

A Randomized Controlled Trial of Effects of DAIry PROtein Products on Liver Disease Severity and Metabolism in Patients With Non-Alcoholic Fatty Liver Disease.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04841915
• Other study ID #: DAIPRO-NAFLD
• Status: Recruiting
• Phase: N/A
• Start date: March 15, 2021
• Est. completion date: July 2023

Study information

• Verified date: March 2021
• Source: University of Aarhus
• Contact: Anders Mellemkjaer, MD
• Phone: +4525305668
• Email: anders.mellemkjaer[@]clin.au.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overarching aim of this project is to investigate effects of dietary interventions on nonalcoholic fatty liver disease (NAFLD) severity and to delineate the relationship with improvements in metabolic aberrations in liver-, fat- and muscle tissue, using a panel of state-of-the art techniques.

The investigators will conduct a randomized clinical trial with three arms to investigate if micellar cassein isolate and whey protein supplementation as part of a high-protein diet during 4 weeks of weight maintenance and 20 weeks of hypocaloric intake (30% energy restriction) inducing modest weight loss (5% of baseline weight) has beneficial effects on NAFLD severity and metabolic aberrations compared to normal diet in NAFLD patients.

It is hypothesized that: (i) a high-protein diet improves liver disease severity and metabolic function compared to a normal protein diet; (ii) Cassein provides greater benefits than whey; and(iii) these effects manifest during both weight maintenance and weight loss.

Description:

To test the hypothesis, state-of-the-art techniques for a comprehensive assessment of liver disease severity and metabolic function will be employed. NAFLD severity and treatment effects will be evaluated on the basis of liver fat content (MR spectroscopy), liver enzymes, liver-specific inflammation and fibrosis markers and fibrosis (fibroscan). Metabolic function will be investigated by basal and insulin mediated whole-body glucose, fatty acid and VLDL-TG turnover, postprandial insulin secretion and clearance (mixed meal test in conjunction with oral minimal modeling). Body composition (total fat mass, leg fat and fat free mass) will be assessed by DEXA-scanning; visceral and upper-body subcutaneous fat by MR-imaging, and fat content of skeletal muscle and liver by MR-spectroscopy. All outcomes will be assessed at baseline, after 4 wk on a eucaloric diet (weight maintenance), and after an additional 20 wk on a hypocaloric diet (5% weight loss), in 54 patients with NAFLD and obesity (BMI ≥30 kg/m2) but without diabetes. Subjects will be block randomized to one of three treatment groups (WPI, MCI, or standard diet, n=18 in each group). A biobank of serum/plasma/DNA including fat and skeletal muscle biopsies will be established for mechanistic analysis in a planned future work-package. Patient related outcomes will include specific questionnaires (CLDQ-NAFLD, SF-36).

All subjects will be phone-contacted on a regular basis by study personnel to monitor progress, resolve problems with the diets, and reinforce compliance; and meet in person with the study dietitians weekly during the weight maintenance phase and biweekly during the weight loss phase to have their body weight measured and receive dietary counselling. Before study initiation, the research teams will put together standardized procedures for patient contact and nutrition counselling, including creating nutrition information leaflets specific to each randomization arm, to ensure uniformity between the study centers. In practice, dietary guidance will be tailored to the individual patient to ensure weight maintenance within 2% of baseline body weight during the first phase (weight stability), and a weight loss of 0.25% per week to reach the target 5% weight loss after 20 weeks during the second phase (weight loss); energy intake will be adjusted as necessary by adding or removing carbohydrate to meet the desired goals. Three-day diet records will be collected before and every 2 weeks during the interventions to evaluate energy and macronutrient intakes. A 3-hour urine sample will be collected during the mixed meal test at baseline, after 4 and 24 weeks in order to monitor dietary protein intake. Participants will be instructed in how to do the sampling and storing the sample cool during the collection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: July 2023
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• BMI = 30 kg/m2

• HbA1C < 48 mmol/mol

• Written informed consent

• Liver steatosis > 10% on MR-spectroscopy

• Premenopausal women will have a negative pregnancy test drawn within 48 hours before the study.

Exclusion Criteria:

• Other chronic liver diseases (HBV, HCV, AIH, PBC, PSC, alcoholic steatosis)

• Known systemic disease exempting hypertension and dyslipidemia.

• Former or active malignant disease

• Alcohol consumption >2 drinks/day for men, 1 drink/day for women, evaluated by AUDIT-C

• Pregnancy

• Any medications including non-prescription medications exempting, birth control medications, antihypertensives and statins. Participants taking statins can participate on the condition of a 2 week pause before the experimental days.

• Estimated glomerular filtration rate <90 ml/min

• Currently smoking

• Blood donation within the last 3 months

• Weight above 130 kg

• Participated in trials using radioactive isotopes within the last 6 months

Related Conditions & MeSH terms

• Caseins
• Diet, High Protein
• Fatty Liver
• Lipoproteins, VLDL
• Liver Diseases
• Metabolic Syndrome
• Non-alcoholic Fatty Liver Disease
• Weight Loss
• Whey

Intervention

Dietary Supplement:
• High-Protein Diet
Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet

Behavioral:
• Clinical dietician
Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
• Weight loss
4 weeks eucaloric diet ~13 MJ/day followed by, 20 weeks hypocaloric diet ~9 MJ/day until 5% weight loss is achieved.

Locations

Country	Name	City	State
Denmark	Aarhus University Hospital, Dept. Hepatology and Gastroenterology	Aarhus N
Denmark	Hvidovre Hospital	Hvidovre

Sponsors (4)

Lead Sponsor	Collaborator
University of Aarhus	Arla Foods, Hvidovre University Hospital, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Steatosis	Changes in the degree of steatosis evaluated by MR spectroscopy	24 weeks
Primary	Liver enzymes	Change is liverenzymes from baseline to week 4 and week 24	24 weeks
Primary	Fibrosis Marker FIB-4	Change in FIB-4 from baseline to week 4 and week 24	24 weeks
Secondary	Insulin Resistance	Changes in Insulin resistance	24 weeks
Secondary	Insulin Secretion	Changes in Insulin Secretion	24 weeks